Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aligos Therapeutics, Inc. - Common stock (NQ:ALGS)

7.580 +0.440 (+6.16%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 85,992
Open 6.970
Bid (Size) 6.800 (4)
Ask (Size) 6.850 (2)
Prev. Close 7.140
Today's Range 6.960 - 7.905
52wk Range 6.760 - 46.80
Shares Outstanding 42,940,089
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aligos Therapeutics Presents Positive Data at APASL 2025
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire

Performance

YTD
-81.0%
-81.0%
1 Month
-47.7%
-47.7%
3 Month
-81.0%
-81.0%
6 Month
-11.8%
-11.8%
1 Year
-69.0%
-69.0%

More News

Read More
Monday's session: top gainers and losers
Via Chartmill
How Is The Market Feeling About Aligos Therapeutics?
Via Benzinga
Nasdaq, S&P 500 Hit 6-Month Lows As Recession Fears Grow: What's Driving Markets Monday?
Via Benzinga
Topics Economy Stocks
Exposures Economy US Equities
Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill
Top movers in Monday's pre-market session
Via Chartmill
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Earnings Scheduled For March 10, 2025
Via Benzinga
Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces $105 Million Private Placement Financing
From Aligos Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Present at Investor Conferences in December
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Appoints David Perry as Vice President of Business Development
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Present at Investor Conferences in October
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
From Aligos Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Aligos Therapeutics, Inc. - Common stock publicly traded?
Yes, Aligos Therapeutics, Inc. - Common stock is publicly traded.
What exchange does Aligos Therapeutics, Inc. - Common stock trade on?
Aligos Therapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aligos Therapeutics, Inc. - Common stock?
The ticker symbol for Aligos Therapeutics, Inc. - Common stock is ALGS on the Nasdaq Stock Market
What is the current price of Aligos Therapeutics, Inc. - Common stock?
The current price of Aligos Therapeutics, Inc. - Common stock is 7.580
When was Aligos Therapeutics, Inc. - Common stock last traded?
The last trade of Aligos Therapeutics, Inc. - Common stock was at 04/02/25 04:00 PM ET
What is the market capitalization of Aligos Therapeutics, Inc. - Common stock?
The market capitalization of Aligos Therapeutics, Inc. - Common stock is 325.49M
How many shares of Aligos Therapeutics, Inc. - Common stock are outstanding?
Aligos Therapeutics, Inc. - Common stock has 325M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS